Increased pro-MMP9 plasma levels are associated with neovascular age-related macular degeneration and with the risk allele of rs142450006 near
Aged
Aged, 80 and over
Alleles
Choroidal Neovascularization
/ enzymology
Enzyme Precursors
/ blood
Enzyme-Linked Immunosorbent Assay
Female
Gene Frequency
Genotyping Techniques
Humans
Male
Matrix Metalloproteinase 9
/ blood
Phenotype
Polymorphism, Single Nucleotide
Tissue Inhibitor of Metalloproteinase-3
/ blood
Wet Macular Degeneration
/ enzymology
Journal
Molecular vision
ISSN: 1090-0535
Titre abrégé: Mol Vis
Pays: United States
ID NLM: 9605351
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
07
2020
accepted:
31
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
6
11
2021
Statut:
epublish
Résumé
To evaluate the plasma levels of matrix metalloproteinase 9 (MMP9) and tissue inhibitors of metalloproteinase 3 (TIMP3) in neovascular age-related macular degeneration (nAMD) patients compared to controls, and to explore the potential effect of AMD-associated genetic variants on MMP9 and TIMP3 protein levels. nAMD and control patients were selected from the European Genetic Database (EUGENDA) based on different genotypes of rs142450006 near nAMD patients had significantly higher total MMP9 levels compared to controls (median 46.58 versus 26.90 ng/ml; p = 0.0004). In addition, the median MMP9 level in the homozygous genotype group for the AMD-risk allele (44.23 ng/ml) was significantly higher than the median for the heterozygous genotype group (26.90 ng/ml; p = 0.0082) and the median for the homozygous group for the non-risk allele (28.55 ng/ml; p = 0.0355). No differences were detected for the active MMP9. TIMP3 levels did not significantly differ between the AMD and control groups, nor between the different genotype groups for rs5754227. The results of our MMP9 analyses indicate that nAMD patients have on average higher systemic MMP9 levels than control individuals, and that this is partly driven by the rs142450006 variant near
Substances chimiques
Enzyme Precursors
0
TIMP3 protein, human
0
Tissue Inhibitor of Metalloproteinase-3
0
pro-matrix metalloproteinase 9
EC 3.4.24.-
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-150Informations de copyright
Copyright © 2021 Molecular Vision.
Références
Circulation. 2003 Apr 1;107(12):1579-85
pubmed: 12668489
Nat Cell Biol. 2000 Oct;2(10):737-44
pubmed: 11025665
Vet Comp Oncol. 2014 Mar;12(1):29-36
pubmed: 22489798
Angiogenesis. 2011 Sep;14(3):235-43
pubmed: 21442180
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Cell Rep. 2020 Jan 28;30(4):1246-1259.e6
pubmed: 31995762
Sensors (Basel). 2018 Sep 27;18(10):
pubmed: 30262739
Pharmacol Ther. 2020 Mar;207:107465
pubmed: 31863819
Mol Cancer Ther. 2005 Sep;4(9):1399-408
pubmed: 16170032
Cancer Res. 1993 Jan 1;53(1):140-6
pubmed: 8416738
Eye (Lond). 2016 Mar;30(3):488-91
pubmed: 26493035
Br J Ophthalmol. 2016 Aug;100(8):1047-51
pubmed: 26614632
Biochim Biophys Acta. 2012 Jan;1825(1):29-36
pubmed: 22020293
BMC Cancer. 2017 Jun 20;17(1):434
pubmed: 28633655
Cancer Res. 2011 Jul 15;71(14):4977-88
pubmed: 21646471
Biomed Res Int. 2017;2017:9352015
pubmed: 28770228
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72
pubmed: 23547785
Acta Ophthalmol. 2019 Feb;97(1):84-90
pubmed: 30288950
Pharmacology. 2009;83(1):18-25
pubmed: 18971601
Int J Cancer. 2003 Sep 20;106(5):745-51
pubmed: 12866035
Cardiovasc Psychiatry Neurol. 2009;2009:904836
pubmed: 20037727
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
QJM. 2008 Oct;101(10):785-91
pubmed: 18676684
J Rheumatol. 1995 Mar;22(3):385-93
pubmed: 7783051
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4360-7
pubmed: 17724228
Mol Cancer Ther. 2018 Jun;17(6):1147-1155
pubmed: 29735645
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
Am J Pathol. 2002 Oct;161(4):1247-53
pubmed: 12368198
Cancer Lett. 2007 Aug 8;253(1):34-42
pubmed: 17306924
Cancer Chemother Pharmacol. 2011 Sep;68(3):619-29
pubmed: 21120482
Int J Cancer. 2009 Jan 15;124(2):306-15
pubmed: 18942717
PLoS One. 2010 Jul 29;5(7):e11860
pubmed: 20686621
J Biol Chem. 2001 Jun 8;276(23):20572-8
pubmed: 11279151
Neurochem Int. 2003 Aug;43(3):191-6
pubmed: 12689599
Physiology (Bethesda). 2013 Nov;28(6):391-403
pubmed: 24186934
Exp Biol Med (Maywood). 2008 Jul;233(7):860-73
pubmed: 18445772
Eur J Cancer. 2008 Sep;44(13):1904-13
pubmed: 18691882
Arch Ophthalmol. 2004 Apr;122(4):598-614
pubmed: 15078679
Lancet. 2012 May 5;379(9827):1728-38
pubmed: 22559899
Eye (Lond). 2008 Jun;22(6):855-9
pubmed: 18597988
PLoS One. 2012;7(2):e31055
pubmed: 22363545
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nat Genet. 1994 Dec;8(4):352-6
pubmed: 7894485
Invest Ophthalmol Vis Sci. 2012 Apr 18;53(4):1953-61
pubmed: 22408008
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2664-76
pubmed: 25766588
PLoS One. 2015 May 11;10(5):e0127063
pubmed: 25961845
Am J Respir Cell Mol Biol. 1999 Mar;20(3):458-64
pubmed: 10030844
Med Sci Monit. 2014 Jun 18;20:1003-16
pubmed: 24938626
Anticancer Res. 2006 Sep-Oct;26(5A):3579-83
pubmed: 17094486
J Cell Physiol. 2008 Dec;217(3):643-51
pubmed: 18636552
Int J Cancer. 2008 May 1;122(9):2050-6
pubmed: 18172859